Within the scope of our study, ACT is represented in 7 clinical trials: 4 exclusively utilize chimeric antigen receptor T-cell (CAR-T) therapies (4.65%), 1 combines CAR-T with chemotherapy (1.16%), and 2 engage tumor-infiltrating lymphocytes (TILs) alongside anti-PD-1 immune checkpoint blockade (ICB) (2.33%). This evidence concerns the gene PDCD1 and neoplasm.